- Conference Call and Webcast to Follow at 5:00 p.m. EST/ 2:00 p.m.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 15, 2016--
Exelixis, Inc. (NASDAQ:EXEL) announced today that its fourth quarter and
full year 2015 financial results will be released on Monday, February
29, 2016 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST,
Exelixis management will host a conference call to discuss the results
and provide a general business update. The conference call will be
accessible via the Internet from the company’s website.
To access the webcast link, log onto www.exelixis.com
and proceed to the Event Calendar page under Investors & Media. Please
connect to the company’s website at least 15 minutes prior to the
conference call to ensure adequate time for any software download that
may be required to listen to the webcast. Alternatively, please call
(855) 793-2457 (domestic) or (631) 485-4921 (international) and provide
the conference call passcode 20111969 to join by phone.
A telephone replay will be available until 11:59 p.m. EST on March 2,
2016. Access numbers for the telephone replay are: (855) 859-2056
(domestic) and (404) 537-3406 (international); the passcode is 20111969.
A webcast replay will also be archived on www.exelixis.com
for one year.
Exelixis, Inc. is a biopharmaceutical company committed to developing
small molecule therapies for the treatment of cancer. Exelixis is
focusing its development and commercialization efforts primarily on
cabozantinib, its wholly owned inhibitor of multiple receptor tyrosine
kinases. Another Exelixis-discovered compound, COTELLIC™ (cobimetinib),
a selective inhibitor of MEK, has been approved in Switzerland, the
United States, and the European Union, and is being evaluated by Roche
and Genentech (a member of the Roche Group) in a broad development
program under a collaboration with Exelixis. For more information,
please visit the company’s website at www.exelixis.com.
Exelixis and the Exelixis logo are registered U.S. trademarks, and
COTELLIC is a U.S. trademark.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160215005300/en/
Source: Exelixis, Inc.
Investor Relations and Corporate
For Exelixis, Inc.